Schernthaner, Guntram

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet

Diabetes Treatment and ManagementPeroxisome Proliferator-Activated Receptors

Cited by 4,129

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): A randomised, open-label study

Buse, J. B., Nauck, M., Forst, T., Sheu, W. H.-H., Shenouda, S. K., Heilmann, C. R., Hoogwerf, B. J., Gao, A., Boardman, M. K., Fineman, M., et al. (2013) · The Lancet

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 565

Effects of Pioglitazone in Patients With Type 2 Diabetes With or Without Previous Stroke: Results From PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)

Wilcox, R., Bousser, M.-G., Betteridge, D. J., Schernthaner, G., Pirags, V., Kupfer, S., & Dormandy, J. (2007) · Stroke

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 475

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

Rosenstock, J., Davies, M., Home, P. D., Larsen, J., Koenen, C., & Schernthaner, G. (2008) · Diabetologia

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 447

Impact of Weight Loss on Inflammatory Proteins and Their Association With the Insulin Resistance Syndrome in Morbidly Obese Patients

Kopp, H. P., Kopp, C. W., Festa, A., Krzyzanowska, K., Kriwanek, S., Minar, E., Roka, R., & Schernthaner, G. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology

Adipokines, Inflammation, and Metabolic DiseasesBariatric Surgery and Outcomes

Cited by 427

Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes

Sinclair, A., Morley, J. E., Rodriguez-Mañas, L., Paolisso, G., Bayer, T., Zeyfang, A., Bourdel-Marchasson, I., Vischer, U., Woo, J., Chapman, I., et al. (2012) · Journal of the American Medical Directors Association

Diabetes Treatment and ManagementDiabetes Management and Education

Cited by 422

Hypoglycemia and cardiovascular risks

Frier, B. M., Schernthaner, G., & Heller, S. R. (2011) · Diabetes Care

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 381

Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls

Bannister, C. A., Holden, S. E., Jenkins‐Jones, S., Morgan, C. L., Halcox, J. P., Schernthaner, G., Mukherjee, J., & Currie, C. J. (2014) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementMetabolism, Diabetes, and Cancer

Cited by 356

Adult-Onset Autoimmune Diabetes in Europe Is Prevalent With a Broad Clinical Phenotype

Hawa, M. I., Kolb, H., Schloot, N., Beyan, H., Paschou, S. A., Buzzetti, R., Mauricio, D., De Leiva, A., Yderstraede, K., Beck-Neilsen, H., et al. (2013) · Diabetes Care

Diabetes and associated disordersDiabetes Management and Research

Cited by 339

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes

Hanefeld, M., Brunetti, P., Schernthaner, G. H., Matthews, D. R., Charbonnel, B. H., & on behalf of the QUARTET Study Group (2004) · Diabetes Care

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 230

Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes

Charbonnel, B., Schernthaner, G., Brunetti, P., Matthews, D. R., Urquhart, R., Tan, M. H., & Hanefeld, M. (2005) · Diabetologia

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 170

Diabetes classification: grey zones, sound and smoke: Action LADA 1

Leslie, R. D. G., Kolb, H., Schloot, N. C., Buzzetti, R., Mauricio, D., De Leiva, A., Yderstraede, K., Sarti, C., Thivolet, C., Hadden, D., et al. (2008) · Diabetes/Metabolism Research and Reviews

Diabetes and associated disordersDiabetes Management and Research

Cited by 136

Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes: A Mediation Analysis

Agarwal, R., Tu, W., Farjat, A. E., Farag, Y. M. K., Toto, R., Kaul, S., Lawatscheck, R., Rohwedder, K., Ruilope, L. M., Rossing, P., et al. (2023) · Annals of Internal Medicine

Chronic Kidney Disease and DiabetesHormonal Regulation and Hypertension

Cited by 109

Prevalence of Micronutrient Deficiency in Patients with Morbid Obesity Before Bariatric Surgery

Krzizek, E.-C., Brix, J. M., Herz, C. T., Kopp, H. P., Schernthaner, G.-H., Schernthaner, G., & Ludvik, B. (2018) · Obesity Surgery

Bariatric Surgery and OutcomesNutrition and Health in Aging

Cited by 99

Increase in visfatin after weight loss induced by gastroplastic surgery

Krzyzanowska, K., Mittermayer, F., Krugluger, W., Kopp, H. P., & Schernthaner, G. (2006) · Obesity

Adipokines, Inflammation, and Metabolic DiseasesBariatric Surgery and Outcomes

Cited by 71

Gliclazide modified release: a critical review of pharmacodynamic, metabolic, and vasoprotective effects

Schernthaner, G. (2003) · Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 66

Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study

Simó, R., Guerci, B., Schernthaner, G., Gallwitz, B., Rosas-Guzmàn, J., Dotta, F., Festa, A., Zhou, M., & Kiljański, J. (2015) · Cardiovascular Diabetology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 47

Preprandial vs. postprandial insulin lispro—a comparative crossover trial in patients with Type 1 diabetes

Schernthaner, G., Wein, W., Shnawa, N., Bates, P. C., & Birkett, M. A. (2004) · Diabetic Medicine

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 32